Trial intelligence / Profile preview

Durvalumab + Olaparib Maintenance in ES-SCLC

NCT05245994Phase 2

Key facts

Status: Unknown
Start: Aug 2021
Primary completion: May 2023
Countries: 1
Modality: Small Molecules

Drugs: olaparib
Conditions: small cell lung cancer (SCLC)

Overview

Phase 2, open-label, single-arm trial of olaparib in small cell lung cancer (SCLC). Primary endpoint: Alive and Progression Free at 12 Months. Status: unknown.

Design

1 arm

Study design: Non-randomizedOpen-labelSingle group

Durvalumab + Olaparib Maintenance
Induction with Durvalumab + EP followed by maintenance with Durvalumab + Olaparib

Who it enrols

Adult patients with extensive-stage small-cell lung cancer (ES-SCLC) suitable for platinum-based chemotherapy, with no prior systemic treatment for ES-SCLC, and adequate organ function.

Endpoints

Primary

Alive and Progression Free at 12 Months12 months

Secondary

Progression Free Survival 02 years
Progression Free Survival2 years
Overall Survival2 years
Objective Response Rate2 years

Beyond the preview

Go deeper on NCT05245994.

Full results, competitive context and analysis are in the Gosset platform.

Full results & analysis

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT05245994.